Glutamate as a Therapeutic Substrate in Migraine
International Journal of Molecular Sciences · 26.03.2025 · 26 (7) · 3023
DOI: 10.3390/ijms26073023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.03.2025. Verfasst von Nazia Karsan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Headache Group, Wolfson Sensory, Pain and Regeneration Centre (SPaRC), Institute of Psychiatry, Psychology and Neuroscience, King's College London, L…. Hauptthemen laut MEDLINE: Glutamic Acid, Migraine Disorders. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Recurrent and intense headache is a well appreciated cardinal feature of migraine, a common and incapacitating neurological disorder. Often, there are associated canonical sensory abnormalities, such as light and sound sensitivity, as well as associated nausea. Given this phenotype of disordered sensory processing and, in a third of patients, the phenomenon called aura accompanying migraine attacks, it has been suggested that the pathophysiology of migraine is likely to involve glutamate, the main excitatory neurotransmitter in the central nervous system (CNS). Glutamate plays a role in nociception, central sensitization, and cortical spreading depression (CSD), three processes that are deemed important in migraine biology. With an emphasis on the therapeutic potential of targeting various glutamate receptors in migraine, this review will discuss the currently available literature and emerging findings on the role of targeting glutamatergic pathways for the treatment of migraine. A thorough literature review was carried out on the functions of both metabotropic glutamate receptors (mGluRs), and the ionotropic glutamate receptors (NMDA, AMPA, and kainate) in migraine pathogenesis. The ever-present need for new treatments, the role of glutamate in the migraine aura phenomenon, and the consequences of monogenic migraine mutations on mediating prolonged, complex, or permanent aura are all discussed, culminating in a suggestion that glutamatergic targeting may hold particular promise in the management of migraine aura. There are plausible roles for metabotropic receptors in regulating pain processing in important migraine-related brain structures, like the thalamus and trigeminal nucleus. Similarly, ionotropic receptors contribute to excitatory neurotransmission and neuronal hyperexcitability. Recent studies have shown preclinical and early clinical results for treatments targeting these receptors, but there are still significant issues with treatment response, including drug transport, side effects, and efficacy. With ongoing and emerging discoveries in the field, there is increasing promise of new migraine medications targeting glutamate receptors. For bench to bedside translation in this area, continued study of the molecular basis of migraine, receptor subtypes, and exploration of potential drug delivery methods are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Headache Group, Wolfson Sensory, Pain and Regeneration Centre (SPaRC), Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 9PJ, UK.
- NIHR King's Clinical Research Facility and SLaM Biomedical Research Centre, King's College Hospital, London SE5 9RS, UK.
- Department of Neurology, University of California Los Angeles, Los Angeles, CA 90095, USA.
ORCID-Profile: Nazia Karsan
Zitieren
APA
Karsan, N., Alves, L. B., & Goadsby, P. J. (2025). Glutamate as a Therapeutic Substrate in Migraine. International Journal of Molecular Sciences, 26(7), 3023. https://doi.org/10.3390/ijms26073023
Vancouver
Karsan N, Alves LB, Goadsby PJ. Glutamate as a Therapeutic Substrate in Migraine. International Journal of Molecular Sciences. 2025;26(7):3023. doi:10.3390/ijms26073023
BibTeX
@article{Karsan2025,
author = {Karsan, Nazia and Alves, Luiza Bastos and Goadsby, Peter J},
title = {Glutamate as a Therapeutic Substrate in Migraine},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {7},
pages = {3023},
doi = {10.3390/ijms26073023}
}
EUVIMED